Phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with the progressive autoimmune kidney ...

The ad creatives love cheeky Super Bowl humor for Novartis.

Novartis announced that its investigational drug Vanrafia has successfully demonstrated the ability to slow kidney function ...

The head of biomedical research at Novartis spoke with STAT about AI, pruning the pipeline, and a potential blockbuster.

Breast cancer drug Kisqali outperformed its 2025 sales target by 9%, while a portfolio of recent launches that includes radioligand therapy Pluvicto, kidney disease drugs Fabhalta and Vanrafia, and ...

Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...

The loss of market exclusivity for a trio of big-selling drugs in the last quarter of 2025 dragged down Novartis sales, but ...

The 466,000 sq ft centre will serve as a hub to join Novartis' current R&D sites in Cambridge, Massachusetts, and Basel, ...

Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.

Niowave Inc., a U.S.-based global leader in medical radioisotope production, today announced a new long-term supply agreement with Novartis to deliver Actinium-225 (Ac-225). The agreement provides ...

CORE OPERATING PROFIT: Novartis is expected to report core operating profit--one of its preferred metrics, which strips out exceptional items--of $21.85 billion, according to Visible Alpha. The ...